KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) Equity Average (2017 - 2025)

Historic Equity Average for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to $27.0 million.

  • Cardlytics' Equity Average fell 8069.5% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year decrease of 8069.5%. This contributed to the annual value of $102.4 million for FY2024, which is 4088.07% down from last year.
  • According to the latest figures from Q3 2025, Cardlytics' Equity Average is $27.0 million, which was down 8069.5% from $61.4 million recorded in Q2 2025.
  • Cardlytics' 5-year Equity Average high stood at $729.6 million for Q2 2021, and its period low was $27.0 million during Q3 2025.
  • In the last 5 years, Cardlytics' Equity Average had a median value of $230.7 million in 2023 and averaged $341.2 million.
  • As far as peak fluctuations go, Cardlytics' Equity Average skyrocketed by 44284.19% in 2021, and later tumbled by 8069.5% in 2025.
  • Cardlytics' Equity Average (Quarter) stood at $689.7 million in 2021, then crashed by 42.57% to $396.1 million in 2022, then plummeted by 54.54% to $180.1 million in 2023, then plummeted by 61.21% to $69.8 million in 2024, then tumbled by 61.34% to $27.0 million in 2025.
  • Its Equity Average was $27.0 million in Q3 2025, compared to $61.4 million in Q2 2025 and $67.0 million in Q1 2025.